{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:47:38Z","timestamp":1787726858564,"version":"build-2784847793"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2012,5,18]],"date-time":"2012-05-18T00:00:00Z","timestamp":1337299200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0037207","type":"journal-article","created":{"date-parts":[[2012,5,20]],"date-time":"2012-05-20T11:50:50Z","timestamp":1337514650000},"page":"e37207","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacious Intermittent Dosing of a Novel JAK2 Inhibitor in Mouse Models of Polycythemia Vera"],"prefix":"10.1371","volume":"7","author":[{"given":"Manfred","family":"Kraus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Aleksandrowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Szewczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melaney","family":"Bouthillette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleen M.","family":"Childers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Dolinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Haidle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Kopinja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongwon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjili","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Rung","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"O\u2019Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Otte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon M.","family":"Taoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna A.","family":"Zabierek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weisheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Gary","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,5,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ajh.21129","article-title":"Prevalence of polycythemia vera and essential thrombocythemia.","volume":"83","author":"X Ma","year":"2008","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.2165\/00003495-200666170-00003","article-title":"Polycythaemia vera and essential thrombocythaemia: current treatment strategies.","volume":"66","author":"EI Penninga","year":"2006","journal-title":"Drugs"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.5858\/2006-130-1151-CMOTMD","article-title":"Current management of the myeloproliferative disorders: a case-based review.","volume":"130","author":"L Rice","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.","volume":"109","author":"RA Mesa","year":"2007","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"EJ Baxter","year":"2005","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"C James","year":"2005","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"R Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"RL Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera.","volume":"280","author":"R Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAK2V617F-positive myeloproliferative disease.","volume":"66","author":"TG Bumm","year":"2006","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.","volume":"108","author":"C Lacout","year":"2006","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.","volume":"107","author":"G Wernig","year":"2006","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/1535-7163.MCT-10-0053","article-title":"Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805.","volume":"9","author":"F Baffert","year":"2010","journal-title":"Molecular Cancer Therapeutics"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.","volume":"13","author":"G Wernig","year":"2008","journal-title":"Cancer Cell"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F.","volume":"1","author":"VM Zaleskas","year":"2006","journal-title":"Plos One"},{"key":"ref16","first-page":"2810","article-title":"A Phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera.","volume":"112","author":"R Paquette","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"ref17","first-page":"97","article-title":"A Phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis.","volume":"112","author":"AD Pardanani","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"ref18","first-page":"1762","article-title":"The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia\/essential thrombocythemia myelofibrosis (post PV\/ETMF).","volume":"112","author":"S Verstovsek","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"ref19","article-title":"Discovery of 1-Amino-5<italic>H<\/italic>-pyrido[4,3-<italic>b<\/italic>]indol-4-carboxamide Inhibitors of JAK2 for the Treatment of Myeloproliferative Disorders. J Med Chem.","volume":"7334\u20137349","author":"J Lim","year":"2011","journal-title":"54,"},{"key":"ref20","author":"JR Young","year":"5830"},{"key":"ref21","article-title":"Preparation of 7,8-fused-2,6-naphthyridin-1(2H)-ones as inhibitors of janus kinases.","volume":"2009035575","author":"T Siu","year":"2009","journal-title":"United States patent application WO"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.bcp.2009.04.025","article-title":"An inhibitor of Janus kinase 2 prevents polycythemia in mice.","volume":"78","author":"A Mathur","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.bbadis.2009.08.011","article-title":"Real-time bioluminescence imaging of polycythemia vera development in mice.","volume":"1792","author":"Y Ma","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling.","volume":"228","author":"K Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.","volume":"108","author":"PJ Campbell","year":"2006","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.","volume":"17","author":"A Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.vph.2005.09.002","article-title":"Introduction to JAK\/STAT signaling and the vasculature.","volume":"43","author":"MB Marrero","year":"2005","journal-title":"Vascul Pharmacol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors.","volume":"93","author":"E Parganas","year":"1998","journal-title":"Cell"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.","volume":"302","author":"PS Changelian","year":"2003","journal-title":"Science"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1189\/jlb.0504282","article-title":"The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing.","volume":"76","author":"M Conklyn","year":"2004","journal-title":"J Leukoc Biol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0037207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T23:29:17Z","timestamp":1642289357000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0037207"}},"subtitle":[],"editor":[{"given":"Kevin D.","family":"Bunting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,5,18]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,5,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0037207","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,18]]}}}